Type 1 DiabetesNCT05145374
Multivariable Artificial Pancreas: Detecting and Mitigating Unannounced Physical Activity and Acute Psychological Stress
An observational study of Type 1 Diabetes, run by University of Illinois Chicago at 1 site in United States.
Trial summary
The objective of this proposal is to demonstrate a viable, functionally integrated multivariable artificial pancreas (mvAP) that will address meal, physical activity (PA) and acute psychological stress (APS) challenges without any manual inputs to better regulate glucose levels of people with diabetes. Read more about this study
- Who is it for?
- Ages 20 to 60 years
- Conditions the study is for
- Type 1 Diabetes
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jul 2022to 1 Sep 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 60 years
- All sexes
- No healthy volunteers
- Adult
Study population: Men and Women with Type 1 Diabetes
Who may be able to join
- Men and Women with T1DM
- Insulin pump users
Who cannot join
- Metabolic instability as evidenced by hospitalizations for diabetes or other diabetes-related complications (e.g., diabetic ketoacidosis and hypoglycemic seizures) within the preceding three months;
- Severe macrovascular disease, as evidenced by severe peripheral artery disease; history of myocardial infarction, heart failure, thromboembolic disease, or unstable angina; uncontrolled hypertension; abnormal resting EKG;
- Maximal exercise stress test with significant brady/tachy arrhythmia, ectopic beats, bundle branch block, or signs of acute ischemia;
- Severe microvascular disease as evidenced by history of vision-threatening proliferative or non-proliferative retinal disease; kidney disease;
- Any uncontrolled non-musculoskeletal condition that would limit the subject's ability to participate in the exercise program (e.g., chronic obstructive airways disease);
- Musculoskeletal conditions such as neurological or orthopedic conditions affecting lower limb strength and mobility (e.g., stroke; insensitive foot);
- Pregnancy;
- Documented medical condition or physical impairment that is judged by the health care practitioner to contraindicate exercise.
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
University of Illinois Chicago
Chicago, Illinois, 60612
Laurie T Quinn, PhD, 312-771-6497, lquinn1@uic.edu
About this study
Official title: Multivariable Artificial Pancreas to Detect and Mitigate the Effects of Unannounced Physical Activities and Acute Psychological Stress
The objective of this proposal is to demonstrate a viable, functionally integrated multivariable artificial pancreas (mvAP) that will address meal, physical activity (PA) and acute psychological stress (APS) challenges without any manual inputs to better regulate glucose levels of people with diabetes. Acute psychological stress and many other forms of PA besides planned exercise can affect blood glucose levels and cause challenges to maintaining euglycemia for people with type 1 diabetes mellitus (T1DM). Various PA and APS affect the metabolism and sensitivity to insulin in different ways. Hence, their types, intensities and durations, and their individual and concurrent presence must be detected in order to determine the optimal insulin administration. The mvAP approach provides a well-integrated and user-friendly technology with minimal burden on the user and mitigates the effects of unexpected PA and APS inducements. Twenty subjects with type 1 diabetes (ages 18-60) who use insulin pumps enrolled in this study. The study will take place at the UIC-College of Nursing Diabetes and Exercise Laboratory. The protocol will include 1 screening visit and 5 sessions at the laboratory. The primary activities at each meeting will include: (1) screening; (2) measurement of peak exercise capacity; (3) estimation of maximal strength from submaximal strength tests; (4) Trier Social Stress Test; (5) submaximal bouts of aerobic and resistance exercise, and activities of daily living with and without stress (e.g., mental calculations, video games). These activities will be included visit 3, 4 and 5 as appropriate. In addition, subjects will perform activities at home include: housekeeping chores, stationary bike (if available); treadmill (if available); walking; and light weights (if available). Periodically, the research assistant will call the subject during these times and ask them to perform stress-inducing activities while performing the activity. The stress inducing activities will include mental challenges such as a mathematical computation while performing the activity. The subjects will be called at home 3-5 times during the study. The fully automated algorithm will be tested in a home setting, however, the methodology will be developed and approved for testing later in the study.
Read the detailed description
The development of an artificial pancreas (AP) has gained considerable progress over the last decade. The goal of AP systems is to develop a device that will provide insulin on demand in response to blood glucose levels in the same manner as the own pancreas. The first generation of AP systems, the hybrid closed-loop AP, collects data from continuous glucose monitoring (CGM) devices and relies on manual user inputs for mitigating the effects of meals and physical activities. The objective of this proposal is to demonstrate a viable, functionally integrated multivariable artificial pancreas (mvAP) that will address meal, physical activity (PA) and acute psychological stress (APS) challenges without any manual inputs to better regulate glucose levels of people with diabetes. Acute psychological stress and many other forms of PA besides planned exercise can affect blood glucose levels and cause challenges to maintaining euglycemia for people with type 1 diabetes mellitus (T1DM). Various PA and APS affect the metabolism and sensitivity to insulin in different ways. Hence, their types, intensities and durations, and their individual and concurrent presence must be detected in order to determine the optimal insulin administration. The mvAP approach provides a well-integrated and user-friendly technology with minimal burden on the user and mitigates the effects of unexpected PA and APS inducements. The objective of this proposal is to demonstrate a viable, functionally integrated mvAP that will address meal, PA and APS challenges without any manual inputs to better regulate glucose levels of people with T1DM. Our hypothesis is that a new generation multivariable AP that incorporates real-time detection and determination of the characteristics of PA and APS and mitigation of their effects by automatic control will be more effective in improving glucose control in people with T1DM. Additionally, this technology will be safer compared to APs based exclusively on CGM data, by reducing the number and duration of hypoglycemic and hyperglycemic events. Such mvAP systems can only be developed by using a sophisticated multivariable approach that uses real-time information from CGMs and physiological variables obtained from wearable devices worn in free-living daily life. It is proposed to build on this framework a fully automated mvAP technology that will mitigate meal, PA and APS challenges, including unexpected and unplanned events. The specific aims of the proposed research are: Aim 1. To develop the mvAP algorithms and modules that identify various types of physical activities, acute psychological stress episodes, their concurrent presence and their characteristics in real time. Aim 2a: To conduct open-loop studies in clinic and in free living to expand the types and intensities of PA and APS inducements, to enrich our database with data collected during activities of daily living (alone or coupled with APS), including unplanned spontaneous PA and APS events. Aim 2b:To extend our multivariable glucose-insulin-physiological variables simulator (mGIPsim) for in silico studies of the mvAP for simulating APS inducements and their effects on glucose levels and physiological variable outputs of the simulator. Aim 3: To conduct clinical experiments with the second generation mvAP in clinical settings and in free living to assess the performance of our fully-automated mvAP in closed-loop operation. At this time, IRB approval for Aim 1, 2a and 2b has been obtained. Aim 3 will be conducted at a later date. The clinical studies will take place at the University of Illinois at Chicago (UIC)-College of Nursing and at the subjects' home. The protocol will include 1 screening visit and 5 sessions at the laboratory. Subjects will wear a CGM and both Empatica and Actigraph wristbands throughout the study. The primary activities at each meeting will include: (1) screening; (2)estimation of maximal exercise capacity from sub-maximal exercise tests (bicycle and treadmill); (3) estimation of maximal strength from sub-maximal strength tests; (4) sub-maximal bouts of aerobic and resistance exercise; (5) use of Socially Evaluated Cold Pressor Test; (6) driving simulation; (7) resistance exercise, and activities of daily living with and without stress (e.g., mental calculations, video games); (8) use of GoPro/Dash Cam during driving (if appropriate) and questionnaires.These activities will be included in visit 3, 4 and 5 as appropriate. In addition, subjects will perform activities at home including: housekeeping chores, stationary bike (if available); treadmill (if available); walking; and light weights (if available) and a sleep monitor (Z-Machine Insight+). Periodically, the research assistant will call the subject during these times and ask them to perform stress-inducing activities while performing the activity. The stress inducing activities will include mental challenges such as a mathematical computation while performing the activity. The subjects will be called at home 3-5 times during the study. The fully automated algorithm will be tested in a home setting. Once the methodology is refined, Institutional Review Board (IRB) approval for the Aim 3 will be obtained.
- Conditions
- Type 1 Diabetes
- Keywords
- Physical Activity, Psychological Stress, Artificial Pancreas, Sleep, Stress
- Medical subject headings
- Diabetes Mellitus, Type 1, Motor Activity, Stress, Psychological
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Stressful Stimuli | Participation in meal, exercise, sleep activities alone or in combination with stressful stimuli. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Measurement of Glucose Concentration
- Glucose concentration (mg/dl) will be measured by: Continuous Glucose Monitor
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Dec 2021
- Study start1 Jul 2022
- Primary completion15 Jul 2025 (estimated)
- Study completion1 Sep 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Type 1 DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Illinois Chicago
- Sponsor type
- University, hospital or other
- Collaborators
- Illinois Institute of Technology
- Responsible party
- Principal investigator, Laurie Quinn, University of Illinois Chicago
- Investigators
- Ali Cinar, Principal investigator, Illinois Institute of Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05145374
- Sponsor's protocol ID
- 2021-0415
- Status last verified
- Aug 2024
- First submitted
- 21 Nov 2021
- Last updated
- 28 Aug 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Sevil M, Rashid M, Hajizadeh I, Askari MR, Hobbs N, Brandt R, Park M, Quinn L, Cinar A. Discrimination of simultaneous psychological and physical stressors using wristband biosignals. Comput Methods Programs Biomed. 2021 Feb;199:105898. doi: 10.1016/j.cmpb.2020.105898. Epub 2020 Dec 17.
PubMed 33360529Sevil M, Rashid M, Maloney Z, Hajizadeh I, Samadi S, Askari MR, Hobbs N, Brandt R, Park M, Quinn L, Cinar A. Determining Physical Activity Characteristics from Wristband Data for Use in Automated Insulin Delivery Systems. IEEE Sens J. 2020 Nov;20(21):12859-12870. doi: 10.1109/jsen.2020.3000772. Epub 2020 Jun 8.
PubMed 33100923Rashid M, Samadi S, Sevil M, Hajizadeh I, Kolodziej P, Hobbs N, Maloney Z, Brandt R, Feng J, Park M, Quinn L, Cinar A. Simulation Software for Assessment of Nonlinear and Adaptive Multivariable Control Algorithms: Glucose - Insulin Dynamics in Type 1 Diabetes. Comput Chem Eng. 2019 Nov 2;130:106565. doi: 10.1016/j.compchemeng.2019.106565. Epub 2019 Sep 2.
PubMed 32863472Turksoy K, Hajizadeh I, Hobbs N, Kilkus J, Littlejohn E, Samadi S, Feng J, Sevil M, Lazaro C, Ritthaler J, Hibner B, Devine N, Quinn L, Cinar A. Multivariable Artificial Pancreas for Various Exercise Types and Intensities. Diabetes Technol Ther. 2018 Oct;20(10):662-671. doi: 10.1089/dia.2018.0072. Epub 2018 Sep 6.
PubMed 30188192Brandt R, Park M, Wroblewski K, Quinn L, Tasali E, Cinar A. Sleep quality and glycaemic variability in a real-life setting in adults with type 1 diabetes. Diabetologia. 2021 Oct;64(10):2159-2169. doi: 10.1007/s00125-021-05500-9. Epub 2021 Jun 17.
PubMed 34136937
Study at a glance
From the registry record, last updated by the sponsor on 28 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multivariable Artificial Pancreas to Detect and Mitigate the Effects of Unannounced Physical Activities and Acute Psychological Stress
- ClinicalTrials.gov ID
- NCT05145374
- Acronym / sponsor ID
- 2021-0415
- Conditions
- Type 1 Diabetes
- Keywords
- Physical Activity, Psychological Stress, Artificial Pancreas, Sleep, Stress
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- University of Illinois ChicagoUniversity, hospital or other
- Collaborators
- Illinois Institute of Technology
- Study start
- 1 Jul 2022 (actual)
- Primary completion
- 15 Jul 2025 (estimated)
- Study completion
- 1 Sep 2025 (estimated)
- First posted
- 6 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this proposal is to demonstrate a viable, functionally integrated multivariable artificial pancreas (mvAP) that will address meal, physical activity (PA) and acute psychological stress (APS) challenges without any manual inputs to better regulate glucose levels of people with diabetes. Acute psychological stress and many other forms of PA besides planned exercise can affect blood glucose levels and cause challenges to maintaining euglycemia for people with type 1 diabetes mellitus (T1DM). Various PA and APS affect the metabolism and sensitivity to insulin in different ways. Hence, their types, intensities and durations, and their individual and concurrent presence must be detected in order to determine the optimal insulin administration. The mvAP approach provides a well-integrated and user-friendly technology with minimal burden on the user and mitigates the effects of unexpected PA and APS inducements. Twenty subjects with type 1 diabetes (ages 18-60) who use insulin pumps enrolled in this study. The study will take place at the UIC-College of Nursing Diabetes and Exercise Laboratory. The protocol will include 1 screening visit and 5 sessions at the laboratory. The primary activities at each meeting will include: (1) screening; (2) measurement of peak exercise capacity; (3) estimation of maximal strength from submaximal strength tests; (4) Trier Social Stress Test; (5) submaximal bouts of aerobic and resistance exercise, and activities of daily living with and without stress (e.g., mental calculations, video games). These activities will be included visit 3, 4 and 5 as appropriate. In addition, subjects will perform activities at home include: housekeeping chores, stationary bike (if available); treadmill (if available); walking; and light weights (if available). Periodically, the research assistant will call the subject during these times and ask them to perform stress-inducing activities while performing the activity. The stress inducing activities will include mental challenges such as a mathematical computation while performing the activity. The subjects will be called at home 3-5 times during the study. The fully automated algorithm will be tested in a home setting, however, the methodology will be developed and approved for testing later in the study.
Detailed description
The development of an artificial pancreas (AP) has gained considerable progress over the last decade. The goal of AP systems is to develop a device that will provide insulin on demand in response to blood glucose levels in the same manner as the own pancreas. The first generation of AP systems, the hybrid closed-loop AP, collects data from continuous glucose monitoring (CGM) devices and relies on manual user inputs for mitigating the effects of meals and physical activities. The objective of this proposal is to demonstrate a viable, functionally integrated multivariable artificial pancreas (mvAP) that will address meal, physical activity (PA) and acute psychological stress (APS) challenges without any manual inputs to better regulate glucose levels of people with diabetes. Acute psychological stress and many other forms of PA besides planned exercise can affect blood glucose levels and cause challenges to maintaining euglycemia for people with type 1 diabetes mellitus (T1DM). Various PA and APS affect the metabolism and sensitivity to insulin in different ways. Hence, their types, intensities and durations, and their individual and concurrent presence must be detected in order to determine the optimal insulin administration. The mvAP approach provides a well-integrated and user-friendly technology with minimal burden on the user and mitigates the effects of unexpected PA and APS inducements. The objective of this proposal is to demonstrate a viable, functionally integrated mvAP that will address meal, PA and APS challenges without any manual inputs to better regulate glucose levels of people with T1DM. Our hypothesis is that a new generation multivariable AP that incorporates real-time detection and determination of the characteristics of PA and APS and mitigation of their effects by automatic control will be more effective in improving glucose control in people with T1DM. Additionally, this technology will be safer compared to APs based exclusively on CGM data, by reducing the number and duration of hypoglycemic and hyperglycemic events. Such mvAP systems can only be developed by using a sophisticated multivariable approach that uses real-time information from CGMs and physiological variables obtained from wearable devices worn in free-living daily life. It is proposed to build on this framework a fully automated mvAP technology that will mitigate meal, PA and APS challenges, including unexpected and unplanned events. The specific aims of the proposed research are: Aim 1. To develop the mvAP algorithms and modules that identify various types of physical activities, acute psychological stress episodes, their concurrent presence and their characteristics in real time. Aim 2a: To conduct open-loop studies in clinic and in free living to expand the types and intensities of PA and APS inducements, to enrich our database with data collected during activities of daily living (alone or coupled with APS), including unplanned spontaneous PA and APS events. Aim 2b:To extend our multivariable glucose-insulin-physiological variables simulator (mGIPsim) for in silico studies of the mvAP for simulating APS inducements and their effects on glucose levels and physiological variable outputs of the simulator. Aim 3: To conduct clinical experiments with the second generation mvAP in clinical settings and in free living to assess the performance of our fully-automated mvAP in closed-loop operation. At this time, IRB approval for Aim 1, 2a and 2b has been obtained. Aim 3 will be conducted at a later date. The clinical studies will take place at the University of Illinois at Chicago (UIC)-College of Nursing and at the subjects' home. The protocol will include 1 screening visit and 5 sessions at the laboratory. Subjects will wear a CGM and both Empatica and Actigraph wristbands throughout the study. The primary activities at each meeting will include: (1) screening; (2)estimation of maximal exercise capacity from sub-maximal exercise tests (bicycle and treadmill); (3) estimation of maximal strength from sub-maximal strength tests; (4) sub-maximal bouts of aerobic and resistance exercise; (5) use of Socially Evaluated Cold Pressor Test; (6) driving simulation; (7) resistance exercise, and activities of daily living with and without stress (e.g., mental calculations, video games); (8) use of GoPro/Dash Cam during driving (if appropriate) and questionnaires.These activities will be included in visit 3, 4 and 5 as appropriate. In addition, subjects will perform activities at home including: housekeeping chores, stationary bike (if available); treadmill (if available); walking; and light weights (if available) and a sleep monitor (Z-Machine Insight+). Periodically, the research assistant will call the subject during these times and ask them to perform stress-inducing activities while performing the activity. The stress inducing activities will include mental challenges such as a mathematical computation while performing the activity. The subjects will be called at home 3-5 times during the study. The fully automated algorithm will be tested in a home setting. Once the methodology is refined, Institutional Review Board (IRB) approval for the Aim 3 will be obtained.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Stressful Stimuli | – | –Participation in meal, exercise, sleep activities alone or in combination with stressful stimuli. |
Who may qualify
- Ages
- 20 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Men and Women with Type 1 Diabetes
Key inclusion criteria (2 listed)
- Men and Women with T1DM
- Insulin pump users
Key exclusion criteria (8 listed)
- Metabolic instability as evidenced by hospitalizations for diabetes or other diabetes-related complications (e.g., diabetic ketoacidosis and hypoglycemic seizures) within the preceding three months;
- Severe macrovascular disease, as evidenced by severe peripheral artery disease; history of myocardial infarction, heart failure, thromboembolic disease, or unstable angina; uncontrolled hypertension; abnormal resting EKG;
- Maximal exercise stress test with significant brady/tachy arrhythmia, ectopic beats, bundle branch block, or signs of acute ischemia;
- Severe microvascular disease as evidenced by history of vision-threatening proliferative or non-proliferative retinal disease; kidney disease;
- Any uncontrolled non-musculoskeletal condition that would limit the subject's ability to participate in the exercise program (e.g., chronic obstructive airways disease);
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Measurement of Glucose Concentration
Time frame: 2 years
• Glucose concentration (mg/dl) will be measured by: Continuous Glucose Monitor
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Aug 2024.
- Background: PubMed 33360529Sevil M, Rashid M, Hajizadeh I, Askari MR, Hobbs N, Brandt R, Park M, Quinn L, Cinar A. Discrimination of simultaneous psychological and physical stressors using wristband biosignals. Comput Methods Programs Biomed. 2021 Feb;199:105898. doi: 10.1016/j.cmpb.2020.105898. Epub 2020 Dec 17.
- Background: PubMed 33100923Sevil M, Rashid M, Maloney Z, Hajizadeh I, Samadi S, Askari MR, Hobbs N, Brandt R, Park M, Quinn L, Cinar A. Determining Physical Activity Characteristics from Wristband Data for Use in Automated Insulin Delivery Systems. IEEE Sens J. 2020 Nov;20(21):12859-12870. doi: 10.1109/jsen.2020.3000772. Epub 2020 Jun 8.
- Background: PubMed 32863472Rashid M, Samadi S, Sevil M, Hajizadeh I, Kolodziej P, Hobbs N, Maloney Z, Brandt R, Feng J, Park M, Quinn L, Cinar A. Simulation Software for Assessment of Nonlinear and Adaptive Multivariable Control Algorithms: Glucose - Insulin Dynamics in Type 1 Diabetes. Comput Chem Eng. 2019 Nov 2;130:106565. doi: 10.1016/j.compchemeng.2019.106565. Epub 2019 Sep 2.
- Background: PubMed 30188192Turksoy K, Hajizadeh I, Hobbs N, Kilkus J, Littlejohn E, Samadi S, Feng J, Sevil M, Lazaro C, Ritthaler J, Hibner B, Devine N, Quinn L, Cinar A. Multivariable Artificial Pancreas for Various Exercise Types and Intensities. Diabetes Technol Ther. 2018 Oct;20(10):662-671. doi: 10.1089/dia.2018.0072. Epub 2018 Sep 6.
- Background: PubMed 34136937Brandt R, Park M, Wroblewski K, Quinn L, Tasali E, Cinar A. Sleep quality and glycaemic variability in a real-life setting in adults with type 1 diabetes. Diabetologia. 2021 Oct;64(10):2159-2169. doi: 10.1007/s00125-021-05500-9. Epub 2021 Jun 17.
- Individual participant dataSharing planned: No
Related trials for Type 1 Diabetes
Not yet recruiting
Care COMPASS Study
Diabetes Mellitus ( Type 1 and Type 2), Hypertension
Recruiting
Starting Technology in At Risk Type 1 Diabetes Study
Diabetes Mellitus, Type 1
Active, not recruiting
Impact of Screening and Multicomponent Exercise on Fall Rates, Fractures, and Cardiovascular Health in Diabetes
Type 2 Diabetes, Osteoporosis
Not yet recruitingPhase 1/2
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes
Healthy Volunteers and Diabetes Participants
RecruitingPhase 4
Cholesterol Lowering and Residual Risk in Diabetes, Type 1
Type 1 Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ali Cinar principal investigator
Illinois Institute of Technology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Type 1 Diabetes, run by University of Illinois Chicago at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 28 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Laurie Quinn, PhD (3127716497, lquinn1@uic.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Measurement of Glucose Concentration (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05145374, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2024.